• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

左心心肌病的血流动力学

Hemodynamics in Left-Sided Cardiomyopathies.

作者信息

Del Monaco Guido, Amata Francesco, Battaglia Vincenzo, Panico Cristina, Condorelli Gianluigi, Pinto Giuseppe

机构信息

IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) Humanitas Research Hospital, 20089 Rozzano-Milan, Italy.

Department of Biomedical Sciences, Humanitas University, 20072 Pieve-Emanuele-Milan, Italy.

出版信息

Rev Cardiovasc Med. 2024 Dec 24;25(12):455. doi: 10.31083/j.rcm2512455. eCollection 2024 Dec.

DOI:10.31083/j.rcm2512455
PMID:39742240
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11683717/
Abstract

Cardiomyopathies, historically regarded as rare, are increasingly recognized due to advances in imaging diagnostics and heightened clinical focus. These conditions, characterized by structural and functional abnormalities of the myocardium, pose significant challenges in both chronic and acute patient management. A thorough understanding of the hemodynamic properties, specifically the pressure-volume relationships, is essential. These relationships provide insights into cardiac function, including ventricular compliance, contractility, and overall cardiovascular performance. Despite their potential utility, pressure-volume curves are underutilized in clinical settings due to the invasive nature of traditional measurement techniques. Recognizing the dynamic nature of cardiomyopathies, with possible transitions between phenotypes, underscores the importance of continuous monitoring and adaptive therapeutic strategies. Enhanced hemodynamic evaluation can facilitate tailored treatment, potentially improving outcomes for patients with these complex cardiac conditions.

摘要

心肌病在历史上被认为较为罕见,但由于成像诊断技术的进步和临床关注度的提高,其越来越受到认可。这些病症以心肌的结构和功能异常为特征,在慢性和急性患者管理中都带来了重大挑战。深入了解血液动力学特性,特别是压力 - 容积关系,至关重要。这些关系有助于洞察心脏功能,包括心室顺应性、收缩性和整体心血管性能。尽管压力 - 容积曲线具有潜在用途,但由于传统测量技术具有侵入性,其在临床环境中的应用未得到充分利用。认识到心肌病的动态性质,其表型之间可能发生转变,凸显了持续监测和适应性治疗策略的重要性。增强的血液动力学评估有助于进行个性化治疗,有可能改善这些复杂心脏疾病患者的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11683717/4c4a70698f32/2153-8174-25-12-455-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11683717/56a7d34e1275/2153-8174-25-12-455-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11683717/7c7414ca46dc/2153-8174-25-12-455-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11683717/4c4a70698f32/2153-8174-25-12-455-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11683717/56a7d34e1275/2153-8174-25-12-455-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11683717/7c7414ca46dc/2153-8174-25-12-455-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11683717/4c4a70698f32/2153-8174-25-12-455-g3.jpg

相似文献

1
Hemodynamics in Left-Sided Cardiomyopathies.左心心肌病的血流动力学
Rev Cardiovasc Med. 2024 Dec 24;25(12):455. doi: 10.31083/j.rcm2512455. eCollection 2024 Dec.
2
The right ventricle in "Left-sided" cardiomyopathies: The dark side of the moon.“左侧”心肌病中的右心室:月亮的暗面。
Trends Cardiovasc Med. 2021 Nov;31(8):476-484. doi: 10.1016/j.tcm.2020.10.003. Epub 2020 Oct 13.
3
Clinical features of isolated noncompaction of the ventricular myocardium: long-term clinical course, hemodynamic properties, and genetic background.孤立性心室心肌致密化不全的临床特征:长期临床病程、血流动力学特性及遗传背景。
J Am Coll Cardiol. 1999 Jul;34(1):233-40. doi: 10.1016/s0735-1097(99)00170-9.
4
[Is a totally non-invasive assessment of the hemodynamic profile possible in patients with chronic heart failure?].[对于慢性心力衰竭患者,是否有可能进行完全无创的血流动力学评估?]
Ital Heart J Suppl. 2000 Nov;1(11):1395-403.
5
[Complex hemodynamic analysis of left ventricular systole in hypertrophic cardiopathy--clinical implications].肥厚型心肌病左心室收缩期的复杂血流动力学分析——临床意义
Kardiol Pol. 1990;33(5):288-302.
6
Cardiac amyloidosis, contrictive pericarditis and restrictive cardiomyopathy.心脏淀粉样变性、缩窄性心包炎和限制型心肌病。
Am J Cardiol. 1976 Nov 4;38(5):547-56. doi: 10.1016/s0002-9149(76)80001-x.
7
Angiocardiograms and hemodynamics in idiopathic cardiomyopathy, with reference to histology of biopsied ventricular myocardium.特发性心肌病的心血管造影与血液动力学,并参考活检心室心肌的组织学表现
Jpn Circ J. 1979 Aug;43(8):779-89. doi: 10.1253/jcj.43.779.
8
Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.用于评估心肌活力的正电子发射断层扫描:基于证据的分析。
Ont Health Technol Assess Ser. 2010;10(16):1-80. Epub 2010 Jul 1.
9
Biventricular catheterization combined with pressure-volume loop monitoring provides insight into the dynamic effects of left ventricular assist devices ramp on right ventricular function.双心室导管插入术结合压力-容积环监测可深入了解左心室辅助装置升压对右心室功能的动态影响。
Catheter Cardiovasc Interv. 2024 Apr;103(5):799-802. doi: 10.1002/ccd.30993. Epub 2024 Mar 10.
10
[Hemodynamic evaluation in acute myocardial infarct. Application to the treatment of contractile insufficiency syndromes of the left ventricle].[急性心肌梗死的血流动力学评估。在左心室收缩功能不全综合征治疗中的应用]
Arch Inst Cardiol Mex. 1976 Jul-Aug;46(4):414-32.

本文引用的文献

1
Influencing and prognostic factors of end-stage hypertrophic cardiomyopathy.终末期肥厚型心肌病的影响因素及预后因素
ESC Heart Fail. 2024 Dec;11(6):4028-4037. doi: 10.1002/ehf2.15010. Epub 2024 Aug 2.
2
Systemic Light Chain Amyloidosis.系统性轻链型淀粉样变性
N Engl J Med. 2024 Jun 27;390(24):2295-2307. doi: 10.1056/NEJMra2304088.
3
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
2024 年美国心脏协会/美国心脏病学会/美国运动医学会/心律学会/起搏与电生理学会/心血管磁共振学会肥厚型心肌病管理指南:美国心脏协会/美国心脏病学会临床实践指南联合委员会的报告。
J Am Coll Cardiol. 2024 Jun 11;83(23):2324-2405. doi: 10.1016/j.jacc.2024.02.014. Epub 2024 May 8.
4
Effect of dapagliflozin on left ventricular structure and function in patients with non-ischemic dilated cardiomyopathy: An observational study.达格列净对非缺血性扩张型心肌病患者左心室结构和功能的影响:一项观察性研究。
Medicine (Baltimore). 2024 Mar 29;103(13):e37579. doi: 10.1097/MD.0000000000037579.
5
Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis.β受体阻滞剂在心肌淀粉样变患者中的耐受性和有效性:系统评价和荟萃分析。
Int J Cardiol. 2024 May 1;402:131813. doi: 10.1016/j.ijcard.2024.131813. Epub 2024 Jan 24.
6
Looking Back, Going Forward: Understanding Cardiac Pathophysiology from Pressure-Volume Loops.回首过去,展望未来:从压力-容积环理解心脏病理生理学
Biology (Basel). 2024 Jan 19;13(1):55. doi: 10.3390/biology13010055.
7
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.阿伐曲泊帕在转甲状腺素蛋白淀粉样心肌病中的疗效和安全性。
N Engl J Med. 2024 Jan 11;390(2):132-142. doi: 10.1056/NEJMoa2305434.
8
Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy.肥厚型心肌病伴心房颤动的当代管理进展
Circulation. 2023 Nov 28;148(22):1797-1811. doi: 10.1161/CIRCULATIONAHA.123.065037. Epub 2023 Nov 27.
9
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.Patisiran 治疗转甲状腺素蛋白心脏淀粉样变心肌病患者。
N Engl J Med. 2023 Oct 26;389(17):1553-1565. doi: 10.1056/NEJMoa2300757.
10
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.马卡丹特:一种用于梗阻性肥厚型心肌病的首创肌球蛋白抑制剂。
Eur Heart J. 2023 Nov 21;44(44):4622-4633. doi: 10.1093/eurheartj/ehad637.